Found 10 Amyloidosis trials
A listing of Amyloidosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Disease modifying therapies for ATTR transthyretin cardiac amyloidosis (ATTR-CA) promises to make a previously untreatable disease manageable. In general, cardiac amyloidosis of any type has been shown to be underdiagnosed or diagnosed late in the disease process. Our goal of the study is to identify African American (AA) patients who …
Request for collaborative review: Sterling IRB serving as IRB of record.
This is a double blind, randomized, placebo controlled trial in subjects with mild cognitive impairment or dementia due to Alzheimer's disease (AD). AMX0035 is a combination of two compounds, Sodium Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA) that are hypothesized to prevent neuronal death through distinct pathways. AMX0035 is not approved …
You are being asked to take part in this research study because you have ATTR amyloidosis with peripheral neuropathy (nerve damage that occurs in the extremities of the body and may cause pain, such as foot pain or hand pain). Transthyretin (TTR) is a naturally occurring protein. In ATTR amyloidosis, TTR …
We plan to enroll up to 25 (target of 20 fully evaluable) adult subjects in this study who have an established diagnosis of advanced cardiac amyloidosis (AL). Subjects will be included in 2 subject cohorts of approximately 10 subjects each. In one cohort positron emission tomography/computed tomography (PET/CT) imaging will …
BAN2401-G000-301 (Study 301) is an 18-month treatment (Core Study), multicenter, double-blind, placebo-controlled, parallel-group study in subjects with EAD (mild cognitive impairment [MCI] due to AD with intermediate likelihood/Prodromal AD or mild AD dementia) with confirmed amyloid pathology indicated by either positive amyloid load confirmed by amyloid PET assessment or CSF …
New treatments that target the protein tau are beginning to enter human clinical trials. While tau-related therapies hold great promise for AD, clinical trials focusing on pure tauopathies are appealing because these diseases do not exhibit concurrent amyloid pathology. Pure 4 microtubule binding repeat (4R) tauopathies (4RT) include corticobasal degeneration …
The study will enroll cognitively unimpaired individuals who are between the ages of 60-75 years with at least one APOE4 allele (HMs or HTs) and, if HTs, with evidence of elevated brain amyloid. Cognitively unimpaired subjects defined as having a Mini-Mental State Examination (MMSE) total score greater than or equal …
Are you having any trouble with your memory or sleep?This research study will explore whether treating sleep apnea can improve memory. Compensation is up to $300 for the participant's time and up to $100 for the study partner.
